Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium

Clinical Neurology and Neurosurgery

Volumn 111, Issue 5, 2009, Pages 437-441

  Pierre Louis, Serge J C ^a   Brannegan, Richard T ^a   Evans, Arthur T ^a  

^a Jr Hospital of Cook County   (United States)

Author keywords

Divalproex; Epilepsy; Extended release divalproex; Low income population; Medication change; Seizure control; Tremor; Weight change

Indexed keywords

VALPROATE SEMISODIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRAWING; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MONITORING; DRUG PREFERENCE; DRUG SAFETY; EPILEPSY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; MALE; NYSTAGMUS; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; PUBLIC HOSPITAL; QUESTIONNAIRE; SEIZURE; SELF REPORT; SIDE EFFECT; STRUCTURED INTERVIEW; TREMOR; URBAN AREA; WEIGHT CHANGE;

ACTIVITIES OF DAILY LIVING; ADULT; ANTICONVULSANTS; BODY WEIGHT; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DELAYED-ACTION PREPARATIONS; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SEIZURES; TREMOR; VALPROIC ACID; YOUNG ADULT;

EID: 67349180705     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2008.12.009     Document Type: Article

References (15)

1. Freitag FG, Collins SD, Carlson HA, et al. For the Depakote-ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-9.
2. Centorrino F., Kelleher J.P., Berry J.M., et al. Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders. Am J Psychiatry 160 (2003) 1348-1350
3. Horne R.L., and Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. J Clin Psychopharmacol 23 (2003) 176-181
4. Citrome L., Tremeau F., Wynn P.S., et al. A study of the safety, efficacy, and tolerability of switching from the standard delayed-release preparation of divalproex to the extended-release formulation in patients with schizophrenia. J Clin Psychopharmacol 24 (2004) 255-259
5. Stoner S.C., Dubisar B.M., Lea J.W., et al. Extended-release divalproex sodium for mood stabilization. Pharmacotherapy 24 9 (2004) 1147-1153
6. Smith M.C., Centorrino F., Welge J.A., and Collins M.A. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav 5 (2004) 746-751
7. Bain P.G., Findley L.J., Atchison P., et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry 56 (1993) 868-873
8. Thibault M., Blume W., Saint-Hilaire J.M., Zakhari R., and Sommerville K.W. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res 50 (2002) 243-249
9. Kernitsky L., O'Hara K.A., Jiang P., and Pellock J.M. Extended-release divalproex in child and adolescent outpatients with epilepsy. Epilepsia 46 3 (2005) 440-443
10. McCabe P.H., Michel N.C., McNew C.D., and Lehman E.B. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up. Epilepsy Behav 8 (2006) 601-605
11. Dutta S., Reed R.C., and O'Dea R.F. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets: clinical implications. Ann Pharmacother 40 (2006) 619-625
12. Dutta S., Zhang Y., Selness D.S., Lee L.L., Williams L.A., and Sommerville K.W. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 49 (2002) 1-10
13. Dutta S., Reed R.C., and Cavanaugh J.H. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol 44 (2004) 737-742
14. Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., and Ouellette V.L. How often is medication taken as prescribed?. JAMA 261 (1989) 3273-3277
15. Reed R.C., Dutta S., Cavanaugh J.H., et al. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations. Epilepsy Behav 8 (2006) 391-396